Destroy Depression

How To Treat Depression Naturally

Get Instant Access

Aberg-Wistedt A (1982). A double-blind study of zimelidine, a selective serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression: I. Clinical findings. Acta Psych Scand 66:50-65. Alphs LD, Campbell B.J (2002). Clozapine: Treatment of mood symptoms. Psychiatric Ann 32:722-729.

Altamura AC, Percudani M (1993). The use of antidepressants for long-term treatment of recurrent depression: Rationale, current methodologies, and future directions. J Clin Psychiatry 54(suppl 8):29-37.

American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. American Psychiatric Association: Washington DC.

American Psychiatric Association (2000). Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157(Suppl 4).

American Psychiatric Association (2002). Practice Guideline for the Treatment of Patients with Bipolar Disorder (Revision). Am J Psychiatry 159(Suppl 4):1—50.

Angst J (1990). Natural history and epidemiology of depression: Results of community studies. In Cobb J, Goeting N (eds). Prediction and Treatment of Recurrent Depression. Duphar Medical Relations: Southampton, England, pp. 1-9.

Angst J, Baastrup P, Grof P, et al. (1973). The course of monopolar depression and bipolar psychoses. Psychiatr Neurol Neurochir 76:489-500.

Avissar S, Schreiber G (1992). Interaction of antibipolar and antidepressant treatments with receptor-coupled G proteins. Pharmacopsychiatry 25:44-50.

Babyak M, Blumenthal JA, Herman S, Khatri P, Doraiswamy M, Moore K, Craighead WE, Baldewicz TT, Krishnan KR (2000). Exercise treatment for major depression: Maintenance of therapeutic benefit at 10 months. Psychosomatic Med 62:633-638.

Beasley CM, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL (1993). Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: Fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol 13:312-320.

Black DW, Wesner R, Gabel J (1993). The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 54(4):146-149.

Blackwell B (1987). Side effects of antidepressant drugs. In Hales RE, Frances AJ (eds). Psychiatry Update: The American Psychiatric Association Annual Review. American Psychiatric Press: Washington, DC, pp. 724-745.

Bolden-Watson C, Richelson E (1993). Blockade by newly-developed antidepressants of bio-genic amine uptake into rat brain synaptosomes. Life Sci 52:1023-1029.

Bowden CL, Lawson DM, Cunningham M, Owen JR, Tracy KA (2002). The role of divalproex in the treatment of bipolar disorder. Psychiatric Annals 32:742-750.

Bremner JD (1995). A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 56:519-525.

Burrows GD, Maguire KP, Norman TR (1998). Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: A review. J Clin Psychiatry 59(suppl 14):4-7.

Bymaster FP, Drechfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT (2001). Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871-880.

Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711.

Cade JFJ (1949). Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia 2:349-352.

Cabras PL, Hardoy MJ, Hardoy MC, Carta MG (1999). Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: Results of an open-label study. J Clin Psychiatry 60:245-248.

Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD (1999). A doubleblind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Clinical Psychiatry 60:79-78.

Cassidy F, Murray E, Weiner RD, Carrol BJ (1997). Lack of relapse with tryptophan depletion following successful treatment with ECT. Am J Psychiatry 154:1151-1152.

Canive JM, Clark RD, Calais LA, Qualls C, Tuason VB (1998). Bupropion treatment in veterans with posttraumatic stress disorder: An open study. J Clin Psychopharmacol 18:379-383.

Casey DE (1987). Tardive dyskinesia. In Meltzer HY (ed). Psychopharmacology: The Third Generation of Progress. Raven Press: New York, pp. 1411-1419.

Cotzias GC, Van Woert MH, Schiffer LM (1967). Aromatic amino acids and modification of Parkinsonism. N Engl J Med 276(7):374-379.

De Boer Th (1996). The pharmacologic profile of mirtazapine. J Clin Psychiatry 57(suppl 4):19-25.

Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR (1990). Serotonin function and the mechanism of antidepressant action: Reversal of antidepressant induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 47:411 -418.

Delgado PL, Miller HM, Salomon RM, Licinio J, Gelenberg AJ, Charney DS (1993). Monoamines and the mechanism of antidepressant action: Effects of catecholamine depletion on mood in patients treated with antidepressants. Psychopharmacol Bull 29:389-396.

Delgado PL, Miller HM, Salomon RM, Licinio J, Krystal JH, Heninger GR, Charney DS (1999). Tryptophan depletion challenge in depressed patients treated with desipramine or fluoxe-tine: Implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 46:212-220.

Delgado PL, Price LH, Aghajanian, GK, Miller, HM, Salomon, RM, Heninger GR, Charney DS (1994). Serotonin and the neurobiology of depression: Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 51:865-874.

Delgado PL, Moreno FA, Potter R, et al. (1997). Norepinephrine and serotonin in antidepres-sant action: Evidence from neurotransmitter depletion studies. In Briley M, Montgomery SA (eds). Antidepressant Therapy at the Dawn of the Third Millennium. Martin Dunitz: London, pp. 141-163.

Depression Guideline Panel (1993). Depression in primary care: Volume 2: Treatment of major depression. Technical Report Number 5. US Department of Health and Human Resources, Public Health Service: Rockville, M.D.

Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA (2002). Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. J Clin Psychiatry 63:308-315.

Duman RS, Heninger GR, Nestler EJ (1997). A molecular and cellular theory of depression. Arch Gen Psychiatry 54:597-606.

Duman RS, Malberg J, Thome J (1999). Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 46:1181-1191.

Ehringer E, Hornykiewicz O (1960). Verteilung von Noradrenalin and Dopamin (3-Hydroxytyramin): im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des estrapyramidalen Systems. Klin Wschr 38:1236-1239.

Emmanuel NP, Lydiard BR, Ballenger JC (1991). Treatment of social phobia with bupropion. J Clin Psychopharmacol 11:276-277.

Fava M (1996). Somatic symptoms, depression, and antidepressant treatment. J Clin Psychiatry 63:305-307.

Feighner J (1993). The efficacy of venlafaxine in major depression and preliminary findings in the treatment of refractory depression. J Clin Psychiatry 54:123-124.

Ferris RM, Cooper BR (1993). Mechanism of antidepressant activity of bupropion. J Clin Psychiatry Monograph 11:2-14.

Fink M (2001). Convulsive therapy: a review of the first 55 years. J Affective Disord 63:1-15.

Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J (2002). Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 32:653-658.

Fisch RZ (1985). Methylphenidate for medical inpatients. Int J Psychiatry Med 15:75-79.

Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Malinger AG, Thase ME, McEachran AB, Grocinski VJ (1990). Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47:1093-1099.

Frank E, Prien RF, Jarrett DB, Keller MB, Kupfer DJ, Lavori P, Rush AJ, Weissman MM (1991). Conceptualization and rationale for consensus definitions of terms in major depressive disorder: Response, remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48:851-855.

Garvey M, Noyes R Jr, Cook B (1990). Use of psychostimulants in affective disorders. In Amsterdam JD (ed). Pharmacotherapy of Depression. Applications for the Outpatient Practitioner. Marcel Dekker: New York, pp. 159-183.

Galynker CJ II, Ongseng F, Finestone H, Dutta E, Serseni D (1998). Hypofrontality and negative symptoms in major depressive disorder. J Nucl Med 39:608-612.

Gelenberg, AJ, Schoonover SC (1991). Bipolar disorder. In Gelenberg AJ, Bassuk EL, Schoonover SC (eds). The Practitioner's Guide to Psychoactive Drugs, Third Edition. Plenum Medical: New York, pp. 91 -123.

Gelenberg AJ, Kane JM, Keller MB, Lavori P, Rosenbaum JF, Cole K, Lavelle J (1989). Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Eng J Med 321:1489-1493.

George MS, Sackeim HA, Rush AJ, Marangell LB, Nahas Z, Husain MM, Lisanby S, Burt T, Goldman J, Ballenger JC (2000). Vagus nerve stimulation: A new tool for brain research and therapy. Biol Psychiatry 47:287-295.

George MS, Wasserman EM, Williams WA, Callahan A, Ketter TA, Basser P, Hallett M, Post RM (1995). Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport 6:1853-1856.

Golden RN, Rudorfer MV, Sherer MA, Linnoila M, Potter WZ (1988). Bupropion in depression. Arch Gen Psychiatry 45:139-149.

Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA (2002). Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial. J Clin Psychiatry 63:225-231.

Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal J, Rasmussen SA, Heninger GR, Charney DS (1990). Specificity of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder: Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 47:577-585.

Goodwin FK, Jamison, KR (1990). Manic-Depressive Illness. Oxford University Press: New York.

Gorman JM, Korotzer A, Su G (2002). Efficacy comparison of escitalopram and Citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrums 7(suppl 1):40-44.

Grinspoon L, Hedbloom P (1975). The Speed Culture: Amphetamine Use and Abuse in America. Harvard University Press: Cambridge, MA.

Handforth A, DeGiorgio CM, Schachter SC, Uthman BM, Naritoku DK, Tecoma ES, Henry TR, Collins SD, Vaughn BV, Gilmartin RC, Labar DR, Morris GL 3rd, Salinsky MC, Osorio I, Ristanovic RK, Labiner DM, Jones JC, Murphy JV, Ney GC, Wheliss JW (1998). Vagus nerve stimulation therapy for partial-onset seizures: A randomized active-control trial. Neurology 51:48-55.

Henry TR, Bakay RAE, Votaw JR, Pennell PB, Epstein CM, Faber TL, Grafton ST, Hoffman JM (1998). Brain blood flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: I. Acute effects at high and low levels of stimulation. Epilepsia 39:983-990.

Hyman SE, Nestler EJ (1996). Initiation and adaptation: A paradigm for understanding psychotropic drug action. Am J Psychiatry 153:151-162.

Hypericum Depression Trial Study Group (2002). Effect of Hypericum perforatum (St John's wort): In major depressive disorder: A randomized controlled trial. JAMA 287: 1807-1814.

Ishihara K, Sasa M (1999). Mechanism underlying the therapeutic effects of electroconvulsive therapy (ECT) on depression. Jpn J Pharmacol 80:185-189.

Kalus O, Asnis GM, Robinson E, Kahn R et al. (1991). Desipramine treatment in panic disorder. JAffDis 21:239-244.

Katon W, Raskind M (1980). Treatment of depression in the medically ill elderly with methylphenidate. Am J Psychiatry 137:963-965.

Kaufmann MW, Murray GB, Cassem NH (1982). Use of psychostimulants in medically ill depressed patients. Psychosomatics 23:817-819.

Keller MB (2001). Long-term treatment of recurrent and chronic depression. J Clin Psychiatry 62(Suppl 24):3-5.

Keller MB, Shapiro RW, Lavori PW, et al. (1982). Recovery in major depressive disorder: Analysis with the life table and regression models. Arch Gen Psychiatry 39:905-910.

Kraepelin E (1921). Manic-Depressive Insanity and Paranoia. Barclay RM (trans), Robertson GM (ed). Livingstone: Edinburgh, reprinted Arno Press: New York, 1976.

Krahl SE, Clark KB, Smith DC, Browning RA (1998). Locus coeruleus lesions suppress the seizure attenuating effects of vagus nerve stimulation. Epilepsia 39:709-714.

Kupfer DJ (1991). Long-term treatment of depression. J Clin Psychiatry 52(Suppl 5): 28-34.

Kupfer DJ, Frank E, Perel JM, Cornes C, Jarrett DB, Malinger AG, Thase ME, McEachran AB, Grocinski VJ (1992). Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 49:769-773.

Leadbetter R, Messenheimer J, Bentley B, Greene P, Huffman R, Spaulding T (2002). Mood-stabilizing properties of lamotrigine: A review of data from controlled clinical trials. Psychiatric Annals 32:766-772.

Lelliott PT, WO Montiero WO (1986). Drug treatment of obsessive compulsive disorder. Drugs 31:75-80.

Leonard HL, Swedo SE, Lenane MC, Rettew DC, et al. (1991). A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 48:922-927.

Loomer HP, Saunders JC, Kline NS (1957). A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatric Res Rep 8:129-141.

Lydiard BR, Morton WA, Emmanuel NP, Zealberg JJ, et al. (1993). Preliminary report: Placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull 29:183-188.

Manji HK, Moore GJ, Chen G. (2001). Bipolar disorder: Leads from the molecular and cellular mechanisms of action of mood stabilisers. Br J Psychiatry 178(Suppl 41):s107-s119.

Marangell LB, Rush AJ, George MS, Sackeim HA, Johnson CR, Husain MM, Nahas Z, Lisanby SH (2002). Vagus nerve stimulation (VNS) for major depressive episodes: One year outcomes. Biol Psychiatry 51:280-287.

Marttila M, Jaaskelainen J, Jarvi R, Romanov M, Miettinen E, Sorri P, Ahlfors U (1995). A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol 5:441-446.

Mather AS, Rodriguez C, Guthrie MF, McHarg AM, Reid IC, McMurdo MET (2002). Effects of exercise on depressive symptoms in older adults with poorly responsive depressive disorder: Randomised controlled trial. Br J Psychiatry 180:411-415.

Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S, Jerabek PA (2002). The functional neuroanatomy of the placebo effect. Am J Psychiatry 159:728-37.

McCall WV, Reboussin DM, Weiner RD, Sackeim HA (2000). Titrated moderately suprathresh-old vs fixed high-dose right unilateral electroconvulsive therapy: acute antidepressant and cognitive effects. Arch Gen Psychiatry 57:438-444.

McElroy SL, Dessain EC, Pope HG, Cole JO, Keck PE, Frankenberg FR, Aizley HG, O'Brien S (1991). Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 52:411-414.

Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F (2001). Incidence or sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. J Clin Psychiatry 62(Suppl 3):10-21.

Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM (1991). Biochemical, neuro-physiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 23:191-199.

Nahas Z, Lomarev M, Roberts DR, Shastri A, Lorberbaum JP, Teneback C, McConnell K, Vincent DJ, Li X, George MS, Bohning DE (2001). Unilateral left prefrontal transcranial magnetic stimulation (TMS) produces intensity-dependent bilateral effects as measured by interleaved BOLD fMRI. Biol Psychiatry 50:712-720.

Nelson JC (1999). A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry 46:2301-1308.

Owens MJ, Knight DL, Nemeroff CB (2000). Paroxetine binding to the rat norepinephrine transporter in vivo. Biol Psychiatry 47:842-845.

Owens MJ, Knight DL, Nemeroff CB (2001). Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50:345-350.

Parker G, Roy K, Wilhelm K, Mitchell P (2001). Assessing the comparative effectiveness of antidepressant therapies: a prospective clinical practice study. J Clin Psychiatry 62:117-125.

Persad E (1990). Electroconvulsive therapy in depression. Can J Psychiatry 35:175-182.

Post RM (1992). Anticonvulsants and novel drugs. In Paykel ES (ed). Handbook of Affective Disorders, Second Edition. Churchill Livingstone: Edinburgh, pp. 387-417.

Prien RF, Kupfer DJ (1986). Continuation therapy for major depressive episodes: How long should it be maintained? Am Psychiatry 143:18-23.

Prien RF, Caffey EM, Klett CJ (1973). Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Arch Gen Psychiatry 26:146-153.

Reist C, Kauffmann CD, Haier RJ, Sangdahl C, et al. (1989). A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am J Psychiatry 146:513-516.

Richou H, Ruimy P, Charbaut J, Delisle JP, Brunner H, Patris M, Zivkov M (1995). A multicenter, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Human Psychopharmacol 10:263-271.

Robinson DS, Lerfald SC, Bennett B, Laux D, Devereaux E, Kayser A, Corcella J, Albright D (1991). Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: A double-blind placebo-controlled discontinuation study. Psychopharmacol Bull 27:31-39.

Roose SP, Glassman A (1989). Cardiovascular effects of tricyclic antidepressants in depressed patients. J Clin Psychiatry Monograph Series 7:1-13.

Rudolph RL, Feiger AD (1999). A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of major depression. JAffDis 56:171-181.

Rush AJ, Batey SR, Donahue RMJ, Ascher JA, Carmody TJ, Metz A (2001). Does pretreatment anxiety predict response to either bupropion SR or sertraline? J AffDis 64:81-87.

Rush AJ, George MS, Sackeim HA, Marangell LB, Husain, MM, Giller C, Hahas Z, Haines S, Simpson RK Jr, Goodman R (2000). Vagus nerve stimulation (VNS) for treatment-resistant depression: a multicenter study. Biol Psychiatry 47:276-86.

Schnyer RN, Allen JJB (2001). Acupuncture in the Treatment of Depression: A Manual for Practice and Research, Churchill Livingstone: Edinburgh and New York.

Schulberg HC, Katon W, Simon GE, Rush JT (1998). Treating major depression in primary care practice: An update of the Agency for Health Care Policy and Research practice guidelines. Arch Gen Psychiatry 55:1121-1127.

Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, Russell J, Lydiard RB, Crits-Christoph P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM, Halbreich U (2001). Effectiveness of St John's wort in major depression: A randomized controlled trial. JAMA 285:1978-1986.

Speer AM, Kimbrell TA, Wassermann EM, Repella JD, Willis MW, Herscovitch P, Post RM (2000). Opposite effects of high and low frequency rTMS on regional brain activity in depressed patients. Biol Psychiatry 48:1133-1141.

Stahl SM (1998). Basic psychopharmacology of antidepressants: Part 1. Antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 59(Suppl 4):5-14.

Stahl SM (2002). Does depression hurt? J Clin Psychiatry 63:273-274.

Sternbach H (1991). The serotonin syndrome. Am J Psychiatry 148:705-713.

Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO (1992). Clozapine in the treatment of dysphoric mania. Biol Psychiatry 32:270-280.

Thase ME, Entsuah AR, Rudolph RL (2001). Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Brit J Psychiatry 178:234-241.

Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KNR, Daniel DG, Petty F, Franca C, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V (1999). Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 156:702-709.

Trivedi MH, Rush AJ, Carmody TJ, Donahue RMJ, Bolden-Watson C, House TL, Metz A (2001). Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psychiatry 62:776-781.

Tyrer PJ, Lee I, Edwards JG, Steinberg B, Elliot EJ, Nightingale JH (1980). Prognostic factors determining response to antidepressant drugs in psychiatric out-patients and general practice. JAffDis 2:149-156.

Van Laere K, Vonck K, Boon P, Versijpt J, Dierckx R (2002). Perfusion SPECT changes after acute and chronic vagus nerve stimulation in relation to prestimulus condition and long term clinical efficacy. JNuclMed 43:733-744.

Van Moffaert M, de Wilde J, Vereecken A, Dierick M, Evrard JL, Wilmotte J, Mendelwicz J (1995). Mirtazapine is more effective than trazodone: A double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 5:441-446.

Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M (2002). Reboxe-tine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 63:31-37.

Villarreal G (1995). Desipramine plasma levels and treatment response in panic disorder. Can J Psychiatry 40:110-111.

Wassermann EM (1997). Risk and safety of repetitive transcranial magnetic stimulation: Report and suggested guidelines from the International Workshop on the Safety of Repetitive Tran-scranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol 108: 1-16.

Werstiuk ES, Coote M, Griffith L, Shannon H, Steiner M (1996). Effects of electroconvulsive therapy on peripheral adrenoceptors, plasma, noradrenaline, MHPG and cortisol in depressed patients. Br J Psychiatry 169:758-765.

Wheatley DP, van Moffaert M, Timmerman L, Kremer CME, Mirtazapine Study Group. (1998). Mirtazapine: Efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry 59:306-312.

Whiskey E, Werneke U, Taylor D (2001). A systematic review and meta-analysis of Hypericum perforatum in depression: A comprehensive clinical review. Int Clin Psychopharmacol 16:239-252.

WHO Mental Health Collaborating Centers (1989). Pharmacotherapy of depressive disorders: A consensus statement. JAffDis 17:197-198.

Woods SW, Tesar GE, Murray GB, Cassem NH (1986). Psychostimulant treatment of depressive disorders secondary to medical illness. J Clin Psychiatry 47:12-15.

Yatham LN, Kusumakar V, Calabrese JR, Rao R, Scarrow G, Kroeker G (2002). Third generation anticonvulsants in bipolar disorder: A review of efficacy and summary of clinical recommendations. J Clin Psychiatry 63:275-283.

Zajecka JM (1993). Pharmacology, pharmacokinetics, and safety issues of mood stabilizing agents. Psychiatric Annals 23:79-85.

Was this article helpful?

0 0
Understanding And Treating Bipolar Disorders

Understanding And Treating Bipolar Disorders

Are You Extremely Happy One Moment and Extremely Sad The Next? Are You On Top Of The World Today And Suddenly Down In The Doldrums Tomorrow? Is Bipolar Disorder Really Making Your Life Miserable? Do You Want To Live Normally Once Again? Finally! Discover Some Highly Effective Tips To Get Rid Of Bipolar Disorder And Stay Happy And Excited Always! Dont Let Bipolar Disorder Ruin Your Life Anymore!

Get My Free Ebook

Post a comment